BRAF and breast carcinoma: Kaplan-Meier survival analysis of patients based on BRAF expression levels showed statistically significant DMFS and DSS outcomes in ER+ breast cancer patients (p = .02 and 0.03, respectively), where women with higher expression of the BRAF mRNA responded more poorly to endocrine therapy (Fig 5B–5D).